Secukinumab (AIN-457) for the treatment of Psoriasis

被引：10
|
作者：
Jaleel, Tarannum [1 ]
Elmets, Craig [1 ]
Weinkle, Allison [3 ]
Kassira, Sama [2 ]
Elewski, Boni [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Dermatol, EFH 414,1530 3rd Ave S, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA
[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
来源：
EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 02期
关键词：
pharmacology; IL-17; Th; 17; AIN-457; psoriasis; secukinumab; SEVERE PLAQUE PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PHASE-III; OPEN-LABEL; MULTIPLE-SCLEROSIS; TH17; CELLS; INFLIXIMAB INDUCTION;
D O I：
10.1586/17512433.2016.1129894
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.
引用
收藏
页码：187 / 202
页数：16
相关论文
共 50 条
  • [31] The Selective Anti-IL17A Monoclonal Antibody Secukinumab ( AIN457) Attenuates IL17A-Induced Levels of IL6 in Human Astrocytes
    Elain, Gaelle
    Jeanneau, Karine
    Rutkowska, Aleksandra
    Mir, Anis K.
    Dev, Kumlesh K.
    GLIA, 2014, 62 (05) : 725 - 735
  • [32] Identification immune response genes in psoriasis after treatment with secukinumab
    Wang, Jing
    Liu, Yufang
    Zhang, Yuxin
    Wang, Shiyan
    Kang, Shaomei
    Mi, Ningyu
    Li, Ruxin
    Zou, Yulin
    BMC MEDICAL GENOMICS, 2023, 16 (01)
  • [33] Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety
    Kolbinger, Frank
    Di Padova, Franco
    Deodhar, Atul
    Hawkes, Jason E.
    Huppertz, Christine
    Kuiper, Torsten
    McInnes, Iain B.
    Ritchlin, Christopher T.
    Rosmarin, David
    Schett, Georg
    Carballido, Jose M.
    Hausermann, Peter
    Calonder, Claudio
    Vogel, Beate
    Rondeau, Jean-Michel
    Bruin, Gerard
    PHARMACOLOGY & THERAPEUTICS, 2022, 229
  • [34] Secukinumab in psoriasis: A single-center experience
    Agaoglu, Esra
    Erdogan, Hilal Kaya
    Acer, Ersoy
    Saracoglu, Zeynep Nurhan
    Bilgin, Muzaffer
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2021, 55 (03): : 125 - 129
  • [35] Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study
    Costanzo, Antonio
    Russo, Filomena
    Galluzzo, Marco
    Stingeni, Luca
    Scuderi, Roberta
    Zichichi, Leonardo
    Papini, Manuela
    Di Costanzo, Luisa
    Conti, Andrea
    Burlando, Martina
    Chiricozzi, Andrea
    Gaiani, Francesca Maria
    Mugheddu, Cristina
    Musumeci, Maria Letizia
    Gisondi, Paolo
    Piaserico, Stefano
    Dapavo, Paolo
    Venturini, Marina
    Pagnanelli, Gianluca
    Amerio, Paolo
    Potenza, Concetta
    Peris, Ketty
    Cantoresi, Franca
    Trevisini, Sara
    Loconsole, Francesco
    Offidani, Annamaria
    Mercuri, Santo Raffaele
    Lora, Viviana
    Prignano, Francesca
    Bartezaghi, Marta
    Oliva, Giovanni
    Aloisi, Elisabetta
    Orsenigo, Roberto
    ACTA DERMATO-VENEREOLOGICA, 2021, 101
  • [36] The use of biopharmaceuticals in the treatment of psoriasis
    Partyka, Anna
    Czopek, Anna
    Stanisz-Wallis, Krystyna
    Zagorska, Agnieszka
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2018, 72 : 642 - 658
  • [37] Secukinumab for the treatment of residual psoriasis: a case series
    Malagoli, Piergiorgio
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 : 12 - 13
  • [38] Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review
    Dauden, Esteban
    Ortiz-Salvador, Jose Maria
    Notario, Jaime
    Puig, Lluis
    Santos-Juanes, Jorge
    Herrera-Acosta, Enrique
    Gomez-Labrador, Lara
    Ruiz-Villaverde, Ricardo
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (02)
  • [39] Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
    Kivelevitch, Dario
    Amin, Sima
    Menter, Alan
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2019, 12 : 249 - 253
  • [40] Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing
    Rodriguez-Fernandez, Karine
    Zarzoso-Foj, Javier
    Saez-Bello, Marina
    Mateu-Puchades, Almudena
    Martorell-Calatayud, Antonio
    Merino-Sanjuan, Matilde
    Gras-Colomer, Elena
    Climente-Marti, Monica
    Mangas-Sanjuan, Victor
    PHARMACEUTICS, 2024, 16 (12)
12345